ArticleAmerican heart journal2005
Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial.
Article in American heart journal, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT00552097. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Combination Ezetimibe and High-Dose Simvastatin vs Simvastatin Alone on the Atherosclerotic Process in Subjects With Heterozygous Familial Hypercholesterolemia (The ENHANCE Trial)
Open the trial in the graphWho cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 87 citations in OpenAlex.
- Association of Intima-Media Thickness Measured at the Common Carotid Artery With Incident Carotid Plaque: Individual Participant Data Meta-Analysis of 20 Prospective Studies.Journal of the American Heart Association · 2023Pooled it
- Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.The Cochrane database of systematic reviews · 2018 · on this mapPooled it
- Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond.American journal of preventive cardiology · 2024Article
- The Role of Ezetimibe in the Treatment of Cardiovascular Disease.Current atherosclerosis reports · 2016Review
- Landmark lipid-lowering trials in the primary prevention of cardiovascular disease.Clinical cardiology · 2013Review
- Inhibition of cholesterol absorption: targeting the intestine.Pharmaceutical research · 2012Review
- Therapeutic strategies to deplete macrophages in atherosclerotic plaques.British journal of clinical pharmacology · 2012Review
- Incidental cardiac findings on computed tomography imaging of the thorax.BMC research notes · 2010Article
- Subclinical atherosclerosis: what it is, what it means and what we can do about it.International journal of clinical practice · 2008Review
- Inhibition of intestinal absorption of cholesterol by ezetimibe or bile acids by SC-435 alters lipoprotein metabolism and extends the lifespan of SR-BI/apoE double knockout mice.Atherosclerosis · 2008Article
- ENHANCE and ACCORD: controversy over surrogate end points.Current cardiology reports · 2008Article
- Atherosclerosis regression: is low-density lipoprotein or high-density lipoprotein the answer?Current atherosclerosis reports · 2007Review
- Effective use of combination lipid therapy.Current atherosclerosis reports · 2006Article
- Effective use of combination lipid therapy.Current cardiology reports · 2005Review
- Questioning the importance of LDL cholesterol: don't throw the baby out with the bathwater!Cardiovascular journal of AfricaArticle
- Triglyceride Treatment in the Age of Cholesterol Reduction.Progress in cardiovascular diseasesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLipid lowering through statin therapy significantly reduces the risk of cardiovascular events. The ENHANCE study is an international 2-year, randomized, double-blind, controlled trial designed to test the hypothesis that treatment of hypercholesterolemia by use of 2 complementary agents, ezetimibe (a specific cholesterol absorption inhibitor) and simvastatin (a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor), will result in larger beneficial effects on carotid artery intima-media thickness (CA IMT) than simvastatin monotherapy.
methodsThe study will recruit 725 men and women with heterozygous familial hypercholesterolemia. After a placebo washout period, participants are randomized to receive daily administration of either simvastatin 80 mg and ezetimibe 10 mg or simvastatin 80 mg and placebo. The ENHANCE trial uses novel state-of-the-art single-frame digital image acquisition and rigorous quality assurance and control.
resultsThe primary end point is mean change from baseline to 2 years in CA IMT, using composite measures from the right and left far wall common carotid artery, carotid bulb, and internal carotid artery. Secondary end points include (1) the proportion of participants who exhibit reductions in CA IMT, (2) the change in maximum far wall IMT, (3) the proportion of participants who develop new carotid artery plaques, and (4) the changes in carotid plus common femoral artery IMT.
conclusionsThis study addresses the question of whether a regimen that uses drugs with different mechanisms of action will be of further benefit in terms of atherosclerosis reduction compared to statin monotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.